Viking Global Investors LP Reports 5.4% Stake in Artiva Biotherapeutics, Inc.

On May 18, 2026, Viking Global Investors LP (VGI) and associated reporting persons, including O. Andreas Halvorsen and Rose S. Shabet, filed a Schedule 13G regarding their holdings in Artiva Biotherapeutics, Inc. (ARTV). The filing reports a combined beneficial ownership of 2,604,166 shares of Common Stock, representing 5.4% of the company's outstanding shares. This position was established following an underwritten offering that closed on May 11, 2026. The shares are held directly by Viking Global Opportunities Illiquid Investments Sub-Master LP (VGOP), which owns 1,822,916 shares (3.8%), and Viking Global Opportunities Vintage IV (Aggregator) LP (VGOVIV), which owns 781,250 shares (1.6%). VGI provides managerial services to these entities and maintains shared voting and dispositive power over the shares. The reporting persons indicated that the securities were acquired for investment purposes and not with the intent to change or influence the control of the issuer. This filing marks a significant new position for the Viking Global entities in the biotechnology firm.